May 4, 2023 07:32 AM EDTUpdated 08:12 AM
R&D

Io­n­is chops two PhII pro­grams in acromegaly and be­ta tha­lassemia

Lei Lei Wu

News Reporter

Io­n­is Phar­ma­ceu­ti­cals is cut­ting two pro­grams — a can­di­date for acromegaly and one for be­ta tha­lassemia — ac­cord­ing to its fist quar­ter earn­ings re­port Wednes­day af­ter­noon. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times